Company Encyclopedia
View More
name
NHWA
002262.SZ
Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. The company offers Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc., as well as Iptakalim, an anti-hypertension drug. It also provides penehyquinac acid hydrochloride injection, sufentanil citrate injection, oxeridine fumarate, injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, duloxetine hydrochloride enteric dissolving capsules, olanzapine tablets, midazolam hydrochloride oral solution, clonazepam injection, pregabalin capsules, lacosamide, injection, mivacuride injection, etc. The company’s products are used for treatment of anesthesiology, psychiatry and neurology, as well as APIs.
3.159 T
002262.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking12/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE16.14%A
    • Profit Margin20.41%A
    • Gross Margin78.30%A
  • Growth ScoreB
    • Revenue YoY8.90%B
    • Net Profit YoY4.96%C
    • Total Assets YoY11.70%B
    • Net Assets YoY13.67%B
  • Cash ScoreC
    • Cash Flow Margin489.88%C
    • OCF YoY8.90%B
  • Operating ScoreB
    • Turnover0.7B
  • Debt ScoreA
    • Gearing Ratio11.06%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Nhwa Pharmaceutical's Sulpiride Hydrochloride Tablets Passes Regulatory Consistency Evaluation

    Nhwa Pharmaceutical's Sulpiride Hydrochloride Tablets Passes Regulatory Consistency Evaluation

    marketscreener·
    SZ
    002262
    +0.57%
    marketscreener·
    SZ
    002262
    +0.57%

    Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2025

    Jiangsu Nhwa Pharmaceutical Co., LTD reported earnings for the nine months ending September 30, 2025. Sales increased to CNY 4,470.99 million from CNY 4,145.46 million year-over-year. Net income rose to CNY 1,106.05 million compared to CNY 1,020.11 million last year. Basic and diluted earnings per share from continuing operations were both CNY 1.09, up from CNY 1.01 a year ago.

    marketscreener·
    SZ
    002262
    +0.57%
    marketscreener·
    SZ
    002262
    +0.57%

    NHWA released its performance for the first three quarters, with a net profit attributable to the parent company of 1.106 billion yuan, a year-on-year increase of 8.42%

    According to the Zhitong Finance APP, NHWA released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 4.471 billion yuan, a year-on-year increase of 7.85%. The net profit attributable to shareholders of the listed company was 1.106 billion yuan, a year-on-year increase of 8.42%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.109 billion yuan, a year-on-year increase of 7.59%

    Zhitong·
    SZ
    002262
    +0.57%
    Zhitong·
    SZ
    002262
    +0.57%

    Jiangsu Nhwa Pharmaceutical Q3 Net Profit Up 3.7% Y/Y

    Jiangsu Nhwa Pharmaceutical Co Ltd :SAYS Q3 NET PROFIT UP 3.7% Y/Y

    Reuters·
    SZ
    002262
    +0.57%
    Reuters·
    SZ
    002262
    +0.57%

    NHWA: The hydrochloride of Tizanidine tablets has obtained a drug registration certificate

    According to the Zhitong Finance APP, NHWA announced that the company recently obtained the "Drug Registration Certificate" for the chemical drug Tapentadol Hydrochloride Tablets issued by the National Medical Products Administration. Tapentadol Hydrochloride Tablets are used for the treatment of acute pain in adult patients that is severe enough to require the use of opioid analgesics, as well as for acute pain that cannot be adequately relieved by alternative treatments

    Zhitong·
    SZ
    002262
    +0.57%
    Zhitong·
    SZ
    002262
    +0.57%
    © 2025 Longbridge｜Disclaimer